Skip to Content

Elevance Health Inc

ELV: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$257.00RplwjbJqsvckdd

Elevance Earnings: Medicaid Weakness Offset on Bottom Line, and 2024 Guidance Remains Solid

Narrow-moat Elevance delivered slightly higher fourth-quarter results and 2024 guidance than we were expecting, despite rising medical utilization trends. However, our long-term forecasts and $520 fair value estimate have not changed materially, and recent trades look close to fair value.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of ELV so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center